Updating results

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) for treating type 2 diabetes in adults

Technology appraisal guidance Published May 2016

Microwave ablation for treating liver metastases (IPG553)

Evidence-based recommendations on microwave ablation for treating liver metastases (cancer)

Interventional procedures guidance Published April 2016

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (IPG554)

Evidence-based recommendations on balloon pulmonary angioplasty for treating chronic thromboembolic pulmonary hypertension

Interventional procedures guidance Published April 2016

Percutaneous interlaminar endoscopic lumbar discectomy for sciatica (IPG555)

Evidence-based recommendations on percutaneous interlaminar endoscopic lumbar discectomy for treating sciatica

Interventional procedures guidance Published April 2016

Percutaneous transforaminal endoscopic lumbar discectomy for sciatica (IPG556)

Evidence-based recommendations on percutaneous transforaminal endoscopic lumbar discectomy for sciatica

Interventional procedures guidance Published April 2016

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx), paclitaxel, trabectedin (Yondelis) and gemcitabine...

Technology appraisal guidance Published April 2016

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction

Technology appraisal guidance Published April 2016

Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia (IPG550)

Evidence-based recommendations on endoscopic carbon dioxide laser cricopharyngeal myotomy for relieving oropharyngeal dysphagia (swallowing difficulties)

Interventional procedures guidance Published March 2016

Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis (IPG551)

Evidence-based recommendations on corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery for chronic rhinosinusitis

Interventional procedures guidance Published March 2016

Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552)

Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine

Interventional procedures guidance Published March 2016

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

Evidence-based recommendations on ruxolitinib (Jakavi) for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

Technology appraisal guidance Published March 2016

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Technology appraisal guidance Published April 2001 Last updated March 2016

Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death (IPG549)

Evidence-based recommendations on normothermic extracorporeal heart preservation for transplantation following donation after brainstem death

Interventional procedures guidance Published February 2016

Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction (IPG546)

Evidence-based recommendations on angioplasty and stenting to treat peripheral arterial disease (PAD) causing refractory erectile dysfunction

Interventional procedures guidance Published February 2016

Mechanical clot retrieval for treating acute ischaemic stroke (IPG548)

Evidence-based recommendations on mechanical blood clot retrieval for treating acute ischaemic stroke

Interventional procedures guidance Published February 2016

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Technology appraisal guidance Published February 2016

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Technology appraisal guidance Published February 2016

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016

Percutaneous coblation of the intervertebral disc for low back pain and sciatica (IPG543)

Evidence-based recommendations on percutaneous coblation of the intervertebral disc for low back pain and sciatica

Interventional procedures guidance Published January 2016

Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica (IPG544)

Evidence-based recommendations on percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica

Interventional procedures guidance Published January 2016

Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (IPG545)

Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain

Interventional procedures guidance Published January 2016

Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

Technology appraisal guidance Published January 2016

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Technology appraisal guidance Published January 2016

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.

Technology appraisal guidance Published January 2016

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

Evidence-based recommendations on ramucirumab (Cyramza)

Technology appraisal guidance Published January 2016

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated

Technology appraisal guidance Published January 2016

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

Technology appraisal guidance Published January 2016

Guidance on the use of imatinib for chronic myeloid leukaemia (TA70)

Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)

Technology appraisal guidance Published October 2003 Last updated January 2016

Insertion of a subretinal prosthesis system for retinitis pigmentosa (IPG537)

Evidence-based recommendations on insertion of a subretinal prosthesis system for retinitis pigmentosa (RP)

Interventional procedures guidance Published December 2015

Joint distraction for ankle osteoarthritis (IPG538)

Evidence-based recommendations on joint distraction for ankle osteoarthritis

Interventional procedures guidance Published December 2015

Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (IPG539)

Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma

Interventional procedures guidance Published December 2015

Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease (IPG540)

Evidence-based recommendations on electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease (GORD)

Interventional procedures guidance Published December 2015

Repetitive transcranial magnetic stimulation for depression (IPG542)

Evidence-based recommendations on repetitive transcranial magnetic stimulation for depression

Interventional procedures guidance Published December 2015

Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (IPG541)

Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis

Interventional procedures guidance Published December 2015

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

Technology appraisal guidance Published December 2015

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

Technology appraisal guidance Published December 2015

Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

Evidence-based recommendations on ciclosporin (Ikervis) for treating dry eye disease that has not improved despite treatment with artificial tears

Technology appraisal guidance Published December 2015

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published December 2015

Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes (IPG534)

Evidence-based recommendations on implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes

Interventional procedures guidance Published November 2015

Living-donor liver transplantation (IPG535)

Evidence-based recommendations on living-donor liver transplantation

Interventional procedures guidance Published November 2015

Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (IPG536)

Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention

Interventional procedures guidance Published November 2015

Vortioxetine for treating major depressive episodes (TA367)

Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults

Technology appraisal guidance Published November 2015

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

Technology appraisal guidance Published November 2015

Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

Technology appraisal guidance Published November 2015

Implanting a baroreceptor stimulation device for resistant hypertension (IPG533)

Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension

Interventional procedures guidance Published October 2015

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..

Technology appraisal guidance Published October 2015

Idelalisib for treating chronic lymphocytic leukaemia (TA359)

Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults

Technology appraisal guidance Published October 2015

Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease (ADPKD)

Technology appraisal guidance Published October 2015

Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer (IPG532)

Evidence-based recommendations on low energy contact X-ray brachytherapy (the Papillon technique) for treating early stage rectal cancer

Interventional procedures guidance Published September 2015

Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...

Technology appraisal guidance Published September 2015